Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A MULTICENTER, OPEN-LABEL, POST-MARKETING STUDY TO EVALUATE THE LONG-TERM SAFETY AND JOINT HEALTH WITH ADMINISTRATION OF EMICIZUMAB IN HEMOPHILIA A PEDIATRIC PATIENTS AGED LESS THAN 12 YEARS WITHOUT FVIII INHIBITORS

Next Previous
Trial Profile

A MULTICENTER, OPEN-LABEL, POST-MARKETING STUDY TO EVALUATE THE LONG-TERM SAFETY AND JOINT HEALTH WITH ADMINISTRATION OF EMICIZUMAB IN HEMOPHILIA A PEDIATRIC PATIENTS AGED LESS THAN 12 YEARS WITHOUT FVIII INHIBITORS

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emicizumab (Primary)
  • Indications Haemophilia A
  • Focus Adverse reactions
  • Acronyms AOZORA

Most Recent Events

  • 12 Dec 2023 Interim results assessing data cut-off of week 145 with 10 participants from HOHOEMI and 20 newly enrolled participants confirming the safety profile of emicizumab, presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 13 Dec 2022 Interim results assessing the 3-year joint evaluation results of the 10 participants who continued from HOHOEMI study presented at the 64th American Society of Hematology Annual Meeting and Exposition
  • 23 Dec 2021 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top